Docket #: S12-488
Anticancer fragment: Depletion of a tsRNA induces cell death
Researchers in Dr. Mark Kay's lab have developed a patented approach to inducing apoptosis that could represent a new strategy against cancer and other diseases. tRNA-derived small RNAs (tsRNAs) are an abundant class of small non-coding RNAs, but their biological role is not well understood. The inventors have found that depletion of tsRNA derived from LeuCAG-tRNA induces apoptosis. Apoptosis, genetically programed cell death, plays an important role in normal tissue development and homeostasis. Defects in apoptosis are thought to contribute to a wide range of human diseases. The methods and compositions provided offer a new therapeutic approach for treating a variety of diseases including cancer.
Stage of research
The inventors have shown that depletion of tsRNA derived from LeuCAG-tRNA induces apoptosis. Decreasing the levels of this tRNA fragment with an antisense oligonucleotide can slow the growth of liver tumors in mice and, potentially, might be useful in treating human cancer.
Applications
- Therapeutic development for:
- Cancer
- Autoimmune disease
- Hyperplasia
- Macular degeneration
Advantages
- New approach to inducing apoptosis
- New avenue for therapeutic development
- New role for tsRNA
Publications
- Kim HK, Fuchs G, Wang S, Wei W, Zhang Y, Park H, Roy-Chaudhuri B, Li P, Xu J, Chu K, Zhang F, Chua M, So S, Cliff Zhang QC, Sarnow P, and Mark A Kay. A transfer-RNA-derived small RNA regulates ribosome biogenesis. Nature volume 552, pages 57–62 (07 December 2017).
- Kim HK, Xu J, Chu K, Park H, Jang H, Li P, Valdmanis PN, Cliff Zhang QC, and Mark A. Kay. A tRNA-Derived Small RNA Regulates Ribosomal Protein S28 Protein Levels after Translation Initiation in Humans and Mice. Cell Reports volume 29 (12), pages 3816-3824. (17 December 2019).
Related Links
Patents
- Published Application: 20140323555
- Published Application: 20170044530
- Published Application: 20200199594
- Issued: 9,428,537 (USA)
- Issued: 10,633,655 (USA)
- Issued: 10,982,211 (USA)
Similar Technologies
-
An improved CD206 binder for targeted immune checkpoint blockade and delivery to tumor-associated macrophages S23-438An improved CD206 binder for targeted immune checkpoint blockade and delivery to tumor-associated macrophages
-
Myc degradation by long non coding RNA for cancer therapeutics S22-163Myc degradation by long non coding RNA for cancer therapeutics
-
A Method for Suppressing Innate Immune Responses to RNA Therapy S22-415A Method for Suppressing Innate Immune Responses to RNA Therapy